Data for Venetoclax/Azacitidine in Induction-Eligible AML: The PARADIGM Trial

Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, examine data from the phase 2 PARADIGM trial (NCT04801797) comparing venetoclax (Venclexta) plus azacitidine vs standard induction chemotherapy in newly diagnosed, fit patients with acute myeloid leukemia (AML). They discuss key efficacy outcomes, safety considerations, and how these results challenge traditional distinctions between intensive and lower-intensity therapy. They also consider the implications of these findings for frontline treatment decision-making.